- Home
- LGVN vs VIVO Comparison
LGVN vs VIVO Comparison
Compare LGVN & VIVO Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | LGVN | VIVO |
|---|---|---|
| Founded | 2014 | 2014 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Medicinal Chemicals and Botanical Products | Power Generation |
| Sector | Health Care | Utilities |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 34.0M | 37.5M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | LGVN | VIVO |
|---|---|---|
| Price | $0.81 | $4.59 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 1 | 0 |
| Target Price | ★ $3.00 | N/A |
| AVG Volume (30 Days) | 367.9K | ★ 1.7M |
| Earning Date | 05-08-2026 | 05-23-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | ★ 50.76 | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $709,000.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $10.81 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | N/A | ★ N/A |
| 52 Week Low | $0.48 | $1.97 |
| 52 Week High | $1.80 | $5.36 |
Technical Indicators
Market Signals| Indicator | LGVN | VIVO |
|---|---|---|
| Relative Strength Index (RSI) | 47.89 | 60.74 |
| Support Level | $0.74 | $2.87 |
| Resistance Level | $0.86 | $5.25 |
| Average True Range (ATR) | 0.06 | 0.56 |
| MACD | -0.00 | 0.11 |
| Stochastic Oscillator | 62.76 | 70.47 |
Price Performance
Historical ComparisonAbout LGVN Longeveron Inc.
Longeveron Inc is a clinical stage biotechnology company developing regenerative medicines to address unmet medical needs. Its investigational product candidate is laromestrocel. Laromestrocel is a proprietary, scalable, allogeneic cellular therapy that has multiple potential modes of action that include pro-vascular, pro-regenerative, and anti-inflammatory mechanisms that collectively appear to promote tissue repair and healing. It is in clinical development of a single investigational product candidate, laromestrocel, for four potential indications: HLHS, Alzheimer's disease (AD), Pediatric Dilated Cardiomyopathy (pediatric DCM), and Aging-related Frailty. It operates in a single operating segment focused on developing regenerative medicines to address unmet medical needs.